Merck & Co., Inc. (MSD)
Profil verwaltet von Bizz IdBeschreibung
Produkte
18 ProdukteBrand: Zinplava. Injection, for intravenous use.
Zulassung eingereicht
Fertigarzneimittel
Geprüft am 2026-10-21
Brand: Enflonsia. Injection, for intramuscular use.
Zulassung eingereicht
Fertigarzneimittel
Geprüft am 2026-10-21
MK-6070. Multi-specific antibody; TriTAC targeting DLL3. Small cell lung cancer. Phase 2. With Daiichi Sankyo.
In Entwicklung
Fertigarzneimittel
Geprüft am 2026-10-21
MK-2400. ADC: anti-B7-H3 IgG1 linked to a topoisomerase I inhibitor. Previously treated extensive-stage SCLC under review in the US; Phase 3 in esophageal and prostate cancer. With Daiichi Sankyo.
Zulassung eingereicht
Fertigarzneimittel
Geprüft am 2026-10-21
Therapeutic protein/conjugate; neuraminidase inhibitor linked to an Fc fragment. Influenza. Phase 3.
In Entwicklung
Fertigarzneimittel
Geprüft am 2026-10-21
High-affinity anti-tau monoclonal antibody. Alzheimer's disease. Phase 2.
In Entwicklung
Fertigarzneimittel
Geprüft am 2026-10-21
ADC; Nectin-4 antibody with topoisomerase I payload. Bladder/prostate cancer. Phase 2.
In Entwicklung
Fertigarzneimittel
Geprüft am 2026-10-21
Fully human anti-CD30L monoclonal antibody. Ulcerative colitis. Phase 2.
In Entwicklung
Fertigarzneimittel
Geprüft am 2026-10-21
Multi-specific antibody; bispecific that activates Tie2 and inhibits VEGF. Neovascular AMD. Phase 2/3.
In Entwicklung
Fertigarzneimittel
Geprüft am 2026-10-21
MK-1022. ADC; anti-HER3 linked to topoisomerase I inhibitor. Breast cancer in Phase 3; other solid tumors in Phase 2. With Daiichi Sankyo.
In Entwicklung
Fertigarzneimittel
Geprüft am 2026-10-21
Brand: Keytruda. Anti-PD-1 monoclonal antibody; intravenous injection. New indications under review in EU/Japan (muscle-invasive bladder, high-risk endometrial, platinum-resistant ovarian cancer); Phase 3 in small cell lung cancer.
Zulassung eingereicht
Fertigarzneimittel
Geprüft am 2026-10-21
Brand: Keytruda Qlex. Pembrolizumab and berahyaluronidase alfa; subcutaneous injection. Hematological malignancies in Phase 2.
Zulassung eingereicht
Fertigarzneimittel
Geprüft am 2026-10-21
MK-5909. ADC; anti-CDH6 linked to topoisomerase I inhibitor. Ovarian cancer in Phase 3; cervical, endometrial, gastric and lung cancer in Phase 2. With Daiichi Sankyo.
In Entwicklung
Fertigarzneimittel
Geprüft am 2026-10-21
MK-3000. Tri-specific antibody, Wnt pathway agonist. Diabetic macular edema. Phase 3.
In Entwicklung
Fertigarzneimittel
Geprüft am 2026-10-21
MK-2870. ADC; anti-TROP2 linked to belotecan-derived payload. Bladder, breast, cervical, endometrial, gastric, NSCLC and ovarian cancer in Phase 3. With Sichuan Kelun-Biotech.
In Entwicklung
Fertigarzneimittel
Geprüft am 2026-10-21
Brand: Winrevair. Therapeutic protein, activin signaling inhibitor; subcutaneous injection. Pulmonary arterial hypertension (HYPERION) under review in the US; PH due to left heart disease in Phase 2.
Zulassung eingereicht
Fertigarzneimittel
Geprüft am 2026-10-21
MK-7240. Anti-TL1A monoclonal antibody. Crohn's disease and ulcerative colitis in Phase 3; axial spondyloarthritis, hidradenitis suppurativa, psoriatic arthritis, rheumatoid arthritis and systemic sclerosis in Phase 2.
In Entwicklung
Fertigarzneimittel
Geprüft am 2026-10-21
MK-2140. ADC; anti-ROR1 linked to MMAE. Hematological malignancies. Phase 3.
In Entwicklung
Fertigarzneimittel
Geprüft am 2026-10-21
Unternehmen kontaktieren
Registrieren Sie sich kostenlos, um die Kontaktdaten dieses Unternehmens zu sehen.
Registrieren - Kostenlos